ALC1 is emerging as an important target for therapeutic intervention strategies in cancer, since ALC1 inactivation exacerbates the cytotoxic effects of clinical PARP inhibitors in HRD cancer cells19–23. The gene discussed is CHD1L; the disease is cancer.